SPRO - Spero Therapeutics Inc

Momentum: Bearish

Recent News

Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics ( SPRO ) Looks Ripe for a Turnaround

Zacks Commentary • 3 weeks, 6 days ago • score: 0.25

The heavy selling pressure might have exhausted for Spero Therapeutics (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multidrug resistant (MDR) bacterial infections and rare diseases in the United States. The company is headquartered in Cambridge, Massachusetts.

52W High

$3.22

52W Low

$0.51

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.46

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.75

EV/Revenue (<3 favorable)

2.74

P/S (TTM) (<3 favorable)

2.49

P/B (<3 favorable)

3.69

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

24.43%

Institutions (25–75% balanced)

15.53%

Shares Outstanding

56,275,000

Float

45,855,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

48,576,000

Gross Profit (TTM)

-31,402,000

EPS (TTM)

-0.98

Profit Margin (>10% good)

-1.10%

Operating Margin (TTM) (higher better)

-0.17%

ROE (TTM) (>15% strong)

-0.95%

EPS YoY (Quarterly) (>10% good)

0.75

Revenue YoY (Quarterly) (>8% good)

0.39

Momentum

Bearish momentum

Value

-0.0617

-0.0550

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025